Concepedia

Michael D. Knierman

MD

Statistics

Publications

35

Citations

3.8K

H-Index

24

Active since

1993

Affiliations

Eli Lilly (United States)(Current)

University of Notre Dame

Indiana University School of Medicine

University of Alabama at Birmingham

National Institute of Allergy and Infectious Diseases

Michael D. Knierman is an author at Eli Lilly (United States) specializing in life sciences, biochemistry, and proteomics.

ORCID

Publications per year

1993–2022

35

Publications

35

Ghrelin octanoylation mediated by an orphan lipid transferase

Jesus A. Gutierrez, Patricia J. Solenberg, Douglas Perkins et al. · Proceedings of the National Academy of Sciences · 2008 · 804 citations · Full text

, , +10

Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor

Amy C. Porter, John‐Michael Sauer, Michael D. Knierman et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 610 citations

, , +10

FGF‐21/FGF‐21 receptor interaction and activation is determined by βKlotho

Alexei Kharitonenkov, James D. Dunbar, Holly A. Bina et al. · Journal of Cellular Physiology · 2007 · 320 citations

, , +14

Comprehensive Label-Free Method for the Relative Quantification of Proteins from Biological Samples

Richard E. Higgs, Michael D. Knierman, Valentina Gelfanova et al. · Journal of Proteome Research · 2005 · 217 citations

, , +17

The Novel Apolipoprotein A5 Is Present in Human Serum, Is Associated with VLDL, HDL, and Chylomicrons, and Circulates at Very Low Concentrations Compared with Other Apolipoproteins

Peter J. O’Brien, William E. Alborn, John H. Sloan et al. · Clinical Chemistry · 2004 · 214 citations · Full text

, , +15

1–5 of 35